Your browser doesn't support javascript.
loading
Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance.
O'Leary, Ashley L; Wattengel, Bethany A; Carter, Michael T; Drye, Alexandra F; Mergenhagen, Kari A.
Afiliación
  • O'Leary AL; Veteran Affairs Western New York Healthcare System, Department of Pharmacy, Buffalo, NY.
  • Wattengel BA; Veteran Affairs Western New York Healthcare System, Department of Pharmacy, Buffalo, NY.
  • Carter MT; Veteran Affairs Western New York Healthcare System, Department of Pharmacy, Buffalo, NY.
  • Drye AF; Veteran Affairs Western New York Healthcare System, Department of Pharmacy, Buffalo, NY.
  • Mergenhagen KA; Veteran Affairs Western New York Healthcare System, Department of Pharmacy, Buffalo, NY. Electronic address: Kari.Mergenhagen@va.gov.
Am J Infect Control ; 51(6): 603-606, 2023 06.
Article en En | MEDLINE | ID: mdl-36075298
ABSTRACT

BACKGROUND:

SARS-CoV-2 Omicron variant has a high transmission rate. In December 2021, Omicron became the dominant variant and quickly accounted for majority of infections in the United States. Drug shortages have led to prioritization of patients for COVID-19 treatment based on risk factors for severe disease.

METHODS:

A retrospective analysis of hospitalized patients with COVID-19 infection at Veteran Affairs Healthcare System across the United States. The primary outcome was 14-day all-cause mortality after the first documented positive SARS-CoV-2 laboratory test. Odds ratios were generated from a multivariate logistic regression of significant factors.

RESULTS:

This study included 12,936 COVID-19 inpatients during a period of Omicron predominance. Age ≥ 65 years is a predictor of 14-day mortality among the vaccinated and unvaccinated population (OR 4.05, CI 3.06-5.45, P ≤ .0001). Triple vaccinated patients demonstrated a 52% decreased risk of death with COVID-19 infection (OR 0.48, CI 0.37-0.61, P ≤ .0001). Patients who were double vaccinated had a 39% decreased risk of death with COVID-19 infection (OR 0.61, CI 0.46-0.80, P = .003).

CONCLUSION:

Advanced age ≥ 65 is the greatest risk factor for mortality in hospitalized COVID-19 patients. COVID-19 vaccination, especially booster doses, was associated with a decreased risk of 14-day mortality compared to double vaccinated or non-vaccinated patients. Results of this study suggest that advanced age should be considered first for prioritization of COVID-19 treatments for Omicron.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Am J Infect Control Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Am J Infect Control Año: 2023 Tipo del documento: Article